Features

The Top 10 Biopharmaceutical Companies

By Gil Y. Roth | July 14, 2011

Our annual look at the 10 biggest biopharmaceutical players

The Top Biophama list is stable this time around; the only change was between CSL and Genzyme, and that was mainly due to the dramatic appreciation of CSL’s reporting currency, the Australian dollar. Scarily, the cumulative revenues of our Top 10 Biopharmas grew a mere 3% in 2010, compared to 4%, 14% and 16% in 2009, 2008 and 2007. That’s the wrong end of the curve.


Genzyme will likely show up on next year’s list, depending on how Sanofi manages its financial reporting once their acquisition is closed. It’s a good thing there are some prospects ready to step in and round out the Top 10. I can already see Dendreon in the on-deck circle, getting ready to step up to the plate.
 

Note: a company qualifies as a “Biopharma” if it makes at least 50% of its drug revenues from selling biologics and vaccines. Small-molecule companies need not apply. 
 

—Gil Y. Roth

Editor


Contributors

Editor: Gil Y. Roth

Associate Editor: Kristin Brooks

Contributing Editor: Derek B. Lowe

 

All profiles written by Gil Roth, except Baxter Bioscience, by Kristin Brooks

The Lowe Down capsules written by Derek Lowe (http://pipeline.corante.com)

Pipeline information compiled by Kristin Brooks

Revenue information compiled by Gil Roth

Top 10 Biopharmas
based on 2010 revenues, in millions
 

1

Roche

$35,629

2

Amgen

$15,053

3

Novo Nordisk

$10,835

4

Merck Serono

$7,641

5

Baxter BioScience

$5,640

6

Biogen Idec

$4,547

7

CSL Ltd.

$3,930

8

Genzyme

$3,417 

9

Allergan

$1,419

10

Alexion Pharma

$541


2010 R&D Expenditures


1

Roche

$7,845

2

Amgen

$2,894

3

Novo Nordisk

$1,712

4

Merck Serono

$1,550

5

Biogen Idec

$1,248

6

Baxter

$915

7

Genzyme

$847

8

Allergan

$805

9

CSL Ltd.

$280

10

Alexion Pharma

$98

Related Packaging:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks